Boston Gamma Knife Center at Tufts Medical Center, Boston, Massachusetts, USA.
J Neurosurg. 2010 Apr;112(4):766-71. doi: 10.3171/2009.8.JNS081706.
Gamma Knife surgery (GKS) has been shown to be effective in treating trigeminal neuralgia (TN). Existing studies have demonstrated success rates of 69.1-85% with median follow-up intervals of 19-60 months. However, series with uniform long-term follow-up data for all patients have been lacking. In the present study the authors examined outcomes in a series of patients with TN who underwent a single GKS treatment followed by a minimum follow-up of 36 months. They used a clinical scale that simplifies the reporting of outcome data for patients with TN.
Fifty-three consecutive patients with typical, intractable TN received a median maximum radiation dose of 80 Gy applied with a single 4-mm isocenter to the affected trigeminal nerve. Follow-up data were obtained by clinical examination and questionnaire. Outcome results were categorized into the following classes (in order of decreasing success): Class 1A, complete pain relief without medications; 1B, complete pain relief with either a decrease or no change in medications; 1C, > or = 50% pain relief without medications; 1D, > or = 50% pain relief with either a decrease or no change in medications; and Class 2, < 50% pain relief and/or increase in medications. Patients with Class 1A-1D outcome (equivalent to Barrow Neurological Institute Grades I-IIIb) were considered to have a good treatment outcome, whereas in patients with Class 2 outcome (equivalent to Barrow Neurological Institute Grades IV and V) treatment was considered to have failed.
A good treatment outcome from initial GKS was achieved in 31 (58.5%) patients for whom the mean follow-up period was 48 months (range 36-66 months). Outcomes at last follow-up were reflected by class status: Class 1A, 32.1% of patients; 1B, 1.9%; 1C, 3.8%; 1D, 20.8%; and Class 2, 41.5%. Statistical analysis showed no difference in outcomes between patients previously treated with microvascular decompression or rhizotomy compared with patients with no previous surgical treatments. Thirty-six percent of patients reported some degree of posttreatment facial numbness. Anesthesia dolorosa did not develop in any patient.
Despite a time-dependent deterioration in the success rate of GKS for medically intractable TN, the authors' study showed that > 50% of patients can be expected to have a good outcome based on their scoring system, with approximately 33% having an ideal outcome (pain free with no need for medications). Long-term data, as those presented here, are important when counseling patients on their treatment options.
伽玛刀手术(GKS)已被证明对治疗三叉神经痛(TN)有效。现有的研究表明,在 19-60 个月的中位随访期内,成功率为 69.1-85%。然而,缺乏所有患者具有统一长期随访数据的系列研究。在本研究中,作者检查了一组接受单次 GKS 治疗并至少随访 36 个月的 TN 患者的结果。他们使用了一种简化 TN 患者报告结果数据的临床量表。
53 例典型、难治性 TN 患者接受了中位最大辐射剂量为 80Gy 的治疗,采用单一 4mm 等中心点应用于受累三叉神经。通过临床检查和问卷调查获得随访数据。结果分为以下几类(按成功率降序排列):1A 级,无药物治疗完全缓解;1B 级,药物治疗完全缓解,减少或不变;1C 级,无药物治疗缓解>50%;1D 级,药物治疗缓解>50%,减少或不变;2 级,缓解<50%和/或药物增加。1A-1D 级(相当于巴罗神经研究所 I-IIIb 级)的患者被认为治疗效果良好,而 2 级(相当于巴罗神经研究所 IV 和 V 级)的患者则被认为治疗失败。
31 例(58.5%)患者在最初的 GKS 治疗后获得了良好的治疗效果,平均随访时间为 48 个月(36-66 个月)。最后一次随访的结果反映在类别状态:1A 级,32.1%的患者;1B 级,1.9%;1C 级,3.8%;1D 级,20.8%;2 级,41.5%。统计学分析显示,与无先前手术治疗的患者相比,先前接受微血管减压或神经根切断术治疗的患者的治疗结果无差异。36%的患者报告有一定程度的治疗后面部麻木。没有患者出现疼痛性感觉丧失。
尽管 GKS 治疗药物难治性 TN 的成功率随时间推移而下降,但本研究表明,根据他们的评分系统,>50%的患者可以获得良好的治疗效果,约 33%的患者有理想的治疗效果(无痛且无需药物治疗)。长期数据(如本研究中提供的数据)在为患者提供治疗选择时非常重要。